Targeted Treatment for
Chronic Rhinosinusitis (CRS)

Targeted Treatment for
Chronic Rhinosinusitis (CRS)

Single Dose, Where Needed, When Needed

Oticara is a clinical-stage biopharmaceutical company developing a new therapy for CRS using a novel intranasal delivery approach.

How We Are Different

CRS can remain difficult to manage — even after sinus surgery and long-term medical therapy. Many patients continue to experience ongoing inflammation and recurring symptoms, including congestion, drainage, and facial pressure.

Oticara’s investigational therapy is a single-dose, ENT-administered intranasal novel corticosteroid formulation designed for precise placement on inflamed sinonasal mucosa. By localizing treatment at the site of disease, it is intended to maximize therapeutic effect while limiting systemic steroid exposure and simplifying treatment with a single in-office dose.

Designed To Be Different And Innovative

  • Targeted, physician-placed delivery, where needed
  • Single-dose eases patient burden
  • Formulated to significantly reduce steroid exposure compared to oral steroids

A New Solution for Patients Who Struggle to Find Relief

Oticara’s product is a semisolid, emulsion-based intranasal formulation engineered for physician placement under endoscopic guidance using a custom applicator. Unlike sprays or rinses, the formulation is designed to remain at the target site to support sustained contact with inflamed sinonasal mucosa.

This quick, patient-friendly, single-dose therapy is designed to deliver a potent corticosteroid directly to the site of disease—maximizing local effect while limiting systemic exposure compared with oral steroids.

Clinical studies have demonstrated rapid and sustained symptom improvement, including in patients whose symptoms have remained uncontrolled despite available therapies.

Initially, we are focused on CRS patients who have tried topical therapies and have undergone sinus surgery but continue to experience persistent symptoms. A sterile formulation is also in development to support healing and recovery following sinus surgery.

Pipeline

CRS Symptom Management

Development
Preclinical
Phase 2 POC
Phase 2
Phase 3
Commercialization

Pipeline

Post-Sinus Surgery Recovery

Development
Preclinical
Phase 2 POC
Phase 2
Phase 3
Commercialization

Oticara is led by a team of pharmaceutical executives with decades of successful product development experience.

Working every day to bring innovative treatments to CRS

Latest News

10/13/2025

Oticara Announces Positive Phase 2 Results

Oticara Announces Positive Phase 2 Results Demonstrating Durable Symptom Improvement for Hard-to-Treat Post-Surgical Chronic Rhinosinusitis

Read more

10/02/2025

Oticara to Present Late-Breaking Phase 2 Data

Oticara to Present Late-Breaking Phase 2 Data on Novel Steroid Nasal Cream for Hard-to-Treat Post-surgical Chronic Rhinosinusitis Patients at AAO-HNSF 2025 Annual Meeting.

Read more

Oticara, Inc.

Austin, TX.

Oticara Australia PTY LTD

Sydney, AUS.

contact@oticara.com